Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-21
DOI
10.1007/s00259-019-04615-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
- (2019) Romain-David Seban et al. OncoImmunology
- Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume
- (2019) Luca Ceriani et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
- (2019) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Alona Zer et al. Clinical Lung Cancer
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer
- (2018) Alexander L. Chin et al. Clinical Lung Cancer
- Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non–Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
- (2018) Akshima Sharma et al. CLINICAL NUCLEAR MEDICINE
- Is it time to change our vision of tumor metabolism prior to immunotherapy?
- (2018) Fabio Grizzi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
- (2018) Alessandro Russo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
- (2018) Bao-Dong Qin et al. MEDICAL HYPOTHESES
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
- (2018) Kyoichi Kaira et al. EUROPEAN JOURNAL OF CANCER
- Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
- (2018) Benjamin Houdu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
- (2018) Dedong Cao et al. OncoImmunology
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
- (2018) Hajira Ilyas et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- CD147-mediated glucose metabolic regulation contributes to the predictive role of 18 F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC
- (2018) Xiaofeng Li et al. MOLECULAR CARCINOGENESIS
- Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
- (2017) Etienne Giroux Leprieur et al. EUROPEAN JOURNAL OF CANCER
- EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
- (2017) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor
- (2017) Laurent Dercle et al. JOURNAL OF NUCLEAR MEDICINE
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- (2016) P. F. Ferrucci et al. ANNALS OF ONCOLOGY
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- (2016) Laurent Dercle et al. EUROPEAN JOURNAL OF CANCER
- Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
- (2016) Jingjie Shang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
- (2016) Anne Winther-Larsen et al. LUNG CANCER
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients
- (2014) Michel Meignan et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial
- (2013) Mitchell Machtay et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
- (2012) Hao Zhang et al. International Journal of Computer Assisted Radiology and Surgery
- Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
- (2011) Shengri Liao et al. ACADEMIC RADIOLOGY
- Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
- (2011) Shengri Liao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small Cell Lung Cancer
- (2010) Christophe Dooms et al. Journal of Thoracic Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started